The report "Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022", The global overactive bladder treatment market is expected to reach USD 4.19 Billion by 2022 from an estimated USD 3.63 Billion in 2017, at a CAGR of 2.9%. The key factors driving the growth of this market include rising prevalence of overactive bladder, aggressive marketing strategies adopted by the players in this market, and the development of innovative therapies. However, the undesired systemic effects caused by the current oral therapies may hinder the growth of this market to a certain extent. —
Browse 53 Market Data Tables and 39 Figures spread through 236 Pages and in-depth TOC on "Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Overactivity) - Global Forecast to 2022"
Early buyers will receive 10% customization on reports.
Download PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=219938791
By pharmacotherapies, the anticholinergics segment accounted for the largest share of the market in 2016
On the basis of pharmacotherapies, the overactive bladder treatment market is broadly segmented into anticholinergics, mirabegron, BOTOX, and neurostimulation. Anticholinergics being the first line of medical treatment on OAB accounted for the largest share of this market in 2016. Among the anticholinergics class of drugs, solifenacin accounted for the largest share of this market owing to its efficacy as compared to the other drugs of the same class.
By disease type, idiopathic bladder overactivity held the largest market share in 2016
Based on disease type of overactive bladder, the market is further categorized into idiopathic and neurogenic bladder overactivity. The neurogenic bladder overactivity segment is further categorized into Parkinson’s disease (PD), stroke, multiple sclerosis (MS), and spinal cord injury that lead to overactive bladder. In 2017, the idiopathic bladder overactivity segment is expected to account for the largest share of the bladder overactivity treatment market. The high share of this segment can be attributed to its high prevalence; women are more susceptible to the condition owing to bladder muscle weakness post pregnancy and menopause.
Speak To Analyst :- http://www.marketsandmarkets.com/speaktoanalyst.asp?id=219938791
The U.S. dominated the market in 2016
The U.S. accounted for the largest share of the overactive bladder treatment market in 2016, followed by Europe and Asia-Pacific. Factors such as its well-established healthcare industry, favorable reimbursement policy, and demographics prone to bladder overactivity are contributing to the large share of the U.S. The rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness on the diseases due to the aggressive marketing campaigns adopted by pharma companies are majorly contributing to the growth of the European overactive bladder treatment market, which holds the second-largest market share.
The key players in the global overactive bladder treatment market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Allergan, Plc. (Ireland), Teva Pharmaceutical Industries Limited (Israel), Mylan N.V. (U.S.), Medtronic plc (Ireland), Endo International plc (Ireland), Sanofi (France), Hisamitsu Pharmaceutical Co., Inc. (Japan), Aurobindo Pharma Limited (India), Apotex Inc. (Canada), and Cogentix Medical, Inc. (U.S.)
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
Name: Mr. Rohan
Email: Send Email
Address: MarketsandMarkets™,701 Pike Street , Suite 2175, Seattle, WA 98101, United States
Release ID: 234441